The Wall Street Journal: Johnson & Johnson vaccine’s latest trial data aren’t as robust as Pfizer’s or Moderna’s but still encouraging

Design is similar to that of the vaccine developed by the University of Oxford and AstraZeneca, which has been cleared for use in the U.K.